Document is current
Any future updates will be listed below
-
Authors
Mark-Adjeli, Princess
Annunziata, Christina
Cole, Christopher
Morelli, Maria Pia
McCoy, Ann
Fantini, Massimo
Mavroukakis, Sharon
Zaki, Anjum
Tsang, Kwong
Arlen, Philip
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03476681 at ClinicalTrials.govnct03476681 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14515
637 Phase IIa combining NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0637
Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.
https://doi.org/10.1200/jco.2024.42.16_suppl.2530
840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression
https://doi.org/10.1136/jitc-2021-sitc2021.840
879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
https://doi.org/10.1136/jitc-2023-sitc2023.0879
Documents that mention this clinical trial
Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14515
637 Phase IIa combining NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0637
Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.
https://doi.org/10.1200/jco.2024.42.16_suppl.2530
840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression
https://doi.org/10.1136/jitc-2021-sitc2021.840
879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
https://doi.org/10.1136/jitc-2023-sitc2023.0879
